Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials

Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials

Collaboration creates a path to combine Signant’s market-leading eCOA and digital endpoint capabilities with Lothar Medical’s three-in-one ALDS PRO respiratory assessment system PHILADELPHIA, and WÜRZBURG, Germany, Sept. 5, 2026 /PRNewswire/ — Signant Health, a leading provider of evidence generation solutions for clinical trials, and Lothar Medical today announced that they have signed a letter of intent …

Signant Health and Lothar Medical Partner to Integrate ALDS PRO System into Clinical Trials

Signant Health and Lothar Medical signed a letter of intent on September 5, 2026, to collaborate on the commercialization of the ALDS PRO respiratory assessment system for use in clinical trials. This partnership integrates Signant Health’s electronic clinical outcome assessment (eCOA) and digital endpoint technology with Lothar Medical’s three-in-one diagnostic device. The agreement establishes a